Clinical Trial Update: Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of anecortave acetate sterile suspension (15 mg) for treatment of rubeosis iridis related to severe diabetic retinopathy and central re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Retinal Vein Occlusion
• Diabetic Retinopathy
• Rubeosis Iridis

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Manhattan Eye, Ear & Throat Hospital | Conditions: Severe Diabetic Retinopathy, Central Retinal Vein Occlusion | Phase 2 | Status: TERMINATED